Do racial and income disparities exist in the application of 21-gene recurrence score?

Investigators assessed whether there are disparities in the use of the 21-gene recurrence score, which can help predict the recurrence risk in patients with early HR+ HER2- breast cancer. They found that there were no clinically significant disparities in race or income level in the application of the 21-gene recurrence score; however, underuse was more evident among older patients, separated/divorced/widowed individuals, and those undergoing mastectomy.